Evaluating Within‐Subject Variability for Narrow Therapeutic Index Drugs-Reference-Cited by-同舟云学术

Evaluating Within‐Subject Variability for Narrow Therapeutic Index Drugs

Published:2019-01-16 Issue:2 Volume:105 Page:411-416
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Jayachandran Priya¹,Okochi Hideaki¹²,Frassetto Lynda A.²,Park Wansu³,Fang Lanyan³,Zhao Liang³,Benet Leslie Z.¹

Affiliation:

1. Department of Bioengineering and Therapeutic SciencesUniversity of California, San Francisco San Francisco California USA

2. Department of MedicineUniversity of California, San Francisco San Francisco California USA

3. Division of Quantitative Methods and ModelingOffice of Research and StandardsOffice of Generic DrugsCenter for Drug Evaluation and Research Silver Spring Maryland USA

Funder

UCSF Benet Fund for Excellence

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1293

Reference8 articles.

1. Novel bioequivalence approach for narrow therapeutic index drugs

2. Yu L.X.Quality and bioequivalence standards for narrow therapeutic index drugs. GPhA 2011 Fall Technical Workshop. Food and Drug Administration.2011. .

3. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide

4. Coumadin (warfarin) [package insert]. (Squibb Bristol‐Myers Princeton NJ 2010). .

5. Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Two-Way Proposal for the Determination of Bioequivalence for Narrow Therapeutic Index Drugs in the European Union;Pharmaceutics;2024-04-28

2. The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the fifth international EUFEPS/AAPS conference;European Journal of Pharmaceutical Sciences;2023-11

3. Potentiel Impact thérapeutique de la substitution en cours de traitement d’un princeps par un générique : limites de la bioéquivalence moyenne pour les médicaments à marge thérapeutique étroite;Bulletin de l'Académie Nationale de Médecine;2023-04

4. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology;European Journal of Drug Metabolism and Pharmacokinetics;2022-08-19

5. Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance;Clinical Pharmacokinetics;2022-06-14